Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon Technologies (CVALF) will showcase its contamination-protection portfolio at the ANCC Magnet & Pathway conference on October 29–31, 2026. The event takes place at McCormick Place in Chicago, where Covalon will exhibit at Booth #327.
The display will include VALGuard Line Guard, CovaClear, IV Clear and SurgiClear dressings, alongside new, larger-sized CovaClear dressings. Covalon expects the larger sizes to help expand its presence among adult patients at acute care hospitals. VALGuard covers IV line connections and catheter hubs against gross contamination; it is not FDA-cleared or approved for infection prevention or CLABSI reduction, meaning reduction of central line-associated bloodstream infections.
Covalon Technologies (CVALF) will show larger CovaClear dressings and contamination-protection products at the Association for Vascular Access meeting on October 2–4.
Its approach pairs VALGuard, a single-use barrier for IV line connections and catheter hubs, with CovaClear silicone dressings that can cover primary IV dressings. The new larger CovaClear sizes offer more coverage options for larger primary dressings and a wider range of line types and insertion sites. Covalon will also display IV Clear dressings. Clinicians and researchers will present on contamination protection and catheter-care topics. VALGuard is not FDA-cleared or approved for infection prevention or CLABSI reduction.
Covalon Technologies (CVALF) reported a retrospective analysis comparing its collagen dressing with five competing dressings in patients with diabetic foot or venous leg ulcers.
The analysis used 9,452 visit-level wound assessments and modeled the probability of reaching more than 50% granulation coverage in wounds with no granulation tissue at baseline. For diabetic foot ulcers, Covalon's dressing had the highest modeled probability at eight and twelve weeks. At twelve weeks, it was roughly three times the next highest comparator. Venous leg ulcer results were directionally consistent. Covalon funded the work, which Intellicure conducted. The findings are associations; residual confounding cannot be excluded, and they do not establish causation.
Covalon Technologies (CVALF) will present at the 2026 Annual Smallcap Discoveries Conference on September 28, 2026, following a strong fiscal Q3 2026.
The company reported revenue of more than $10.0 million, up 20% over the prior-year quarter, with growth across all three sales channels. Gross margin reached 67%, compared with 47% a year earlier. Net income was $2.8 million with diluted EPS of $0.10, versus $0.1 million and $0.00 in the prior-year quarter. Covalon held $19.4 million in cash and had no bank debt as of June 30, 2026.
CEO Brent Ashton will present at 10:00 a.m. PT (1:00 p.m. ET) and join one-on-one investor meetings at the Vancouver conference.
Covalon (OTCQX:CVALF) reported strong fiscal 2026 Q3 results for the period ended June 30, 2026. Revenue rose 20% year-over-year to $10.0 million, with gross margin expanding to 67.2% from 46.5%. Net income increased to $2.8 million from $0.1 million, and diluted EPS reached $0.10, exceeding the total of the prior five quarters combined. Adjusted EBITDA was $3.0 million, more than triple the prior year. Contamination Protection revenue grew 68% year-over-year and 34% sequentially, supporting 51% growth in the US Vascular Access and Surgical Consumables channel. For the nine months, revenue was $25.7 million, net income $4.0 million, and Adjusted EBITDA $4.7 million. Covalon ended Q3 with $19.4 million in cash and no bank debt.
Covalon Technologies (OTCQX: CVALF; TSXV: COV) will release its Q3 Fiscal 2026 results on Thursday, August 27, 2026, before markets open. A results conference call and live webcast will be held the same day at 8:30am ET, with Q&A and a replay available online.
Covalon (OTCQX:CVALF, TSXV:COV) appointed Dr. Murray Miller as an independent director to its Board, subject to TSX Venture Exchange approval. Dr. Miller previously served on the Board from 2010 to 2019 and remains a substantial shareholder.
As compensation for fiscal 2026 director fees, Dr. Miller received 22,222 Deferred Share Units (DSUs) under Covalon’s Amended and Restated Omnibus Long-Term Incentive Plan, vesting 12 months from grant. The DSUs’ deemed value used the June 8, 2026 TSXV closing price of $2.16. Covalon also granted 6,218 DSUs to certain directors to settle LTIP obligations.
Covalon (OTCQX:CVALF) reported fiscal Q2 2026 revenue of $8.7 million, up 15% year-over-year, with gross margin rising to 61.5%. Net income reached $1.1 million and diluted EPS was $0.04. Adjusted EBITDA was $1.3 million. Cash stood at approximately $16.6 million with no bank debt.
The company highlighted rapid adoption of its vascular access Contamination Prevention products, including strong U.S. growth in CovaClear Cover dressings and VALGuard Line Guard, a major U.S. hospital-wide rollout, and supportive clinical and conference exposure.
Covalon (OTCQX:CVALF) will release its Q2 fiscal 2026 results on Thursday, May 21, 2026, before markets open. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and take investor questions.
Covalon Technologies (OTCQX: CVALF) reported commercial and clinical engagement milestones across vascular access, infection prevention, and wound care on April 15, 2026. The company cited strong clinician interest at the Infusion Nurses Society meeting, inclusion of contamination education at APIC and AVA 2026, and SAWC wound care outreach.
Covalon highlighted its VALGuard Line Guard and CovaClear IV Cover dressings as differentiated solutions gaining exposure through key conferences and KOL presentations.